1. Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes
- Author
-
Yusuf, S., Mehta, S.R., Bassand, J.P., Budaj, A., Chrolavicius, S., Fox, K.A.A., Granger, C.B., Joyner, C., Peters, R.J.G., Wallentin, L., Avezum, A., Boden, W., Cardona, E., Ceremuzynski, L., Col, J., Commerford, P.J., Diaz, R., Faxon, D., Flather, M., Fodor, G., Franzosi, M.G., Granger, C., Halon, D., Hunt, D., Karatzas, N., Keltai, M., Kenda, M., Kim, J.H., Lanas, F., Lau, C.P., Lewis, B.S., Morais, J., Moccetti, T., Pais, P., Paolasso, E., Parkhomenko, A., Petrauskiene, B., Piegas, L., Pipilis, A., Robaayah, D., Ruda, M., Rumboldt, Zoran, Rupprecht, H.J., Sitkei, E., Steg, P.G., Swahn, E., Theroux, P., Valentin, V., Varigos, J., Weitz, J., White, H., Widimsky, P., Xavier, D., Zhu, J.R., Ameriso, S., Bonilla, C., Braekken, S., Chan, Y.K., Chen, W., Chenniappan, M., Cohen, E., Cottin, Y., Csiba, L., Czepiel, A., de Raedt, H., Finet, G., Gardinale, E., Gaxiola, E., Gorecki, A., Gregor, P., Happola, O., Heras, M., Himbert, D., Irkin, O., Isaaz, K., Iyengar, S.S., Kalvach, P., Kevers, L., Klosiewicz-Wasek , B., Laine, M., Leys, D., Lundstrom, E., Lušić, Ivo, Lutay, Y., Maggioni, A., Massaro, A., Mayosi, B.M., Moulin, T., Narendra, J., Naslund, U., Peeters, A., Penicka, M., Perakis, A., Petersen, P., Polić, S., Radhakrishnan, S., Renkin, J., Stockins, B., Sundararajan, R., Thygesen, K., Turazza, F., van Belle, E., Vik-Mo, H., Zaborski, J., Sleight, P., Anderson , J.L., Johnstone D., Hirsh, J., de Mets, D., Holmes, D.R., Meeks, B., Afzal, R., Pogue, J., Boccalon, S., Chrysler, K., Cracknell, B., Horsman, C., Hoskin, T., Jedrzejowski. B., Johnson, J., Kotlan, S., Lawrence, M., Smiley, M., Stevens, C., Yallup, R., Connolly, S., Demers, C., Devereaux, P.J., Healey, J., Lonn, E., Magloire, P., McKelvie, R., Morillo, C., Natarajan, M., Rokoss, M., Teo, K., Valettas, N., Velianou, J., Bakula, Miro, Bergovec, M, Lukin Ajvor, Miličević, Goran, Padovan, Milko, and Raguž, M.
- Subjects
ST-segment elevation ,high-risk patients ,unfractionated heparin ,myocardial infarction ,collaborative metaanalysis ,randomized trials ,initial treatment ,american-college ,task-force ,prevention - Abstract
The combined use of anticoagulants, antiplatelet agents, and invasive coronary procedures reduces ischemic coronary events but also increases bleeding in patients with acute coronary syndromes. We therefore assessed whether fondaparinux would preserve the anti-ischemic benefits of enoxaparin while reducing bleeding. We randomly assigned 20, 078 patients with acute coronary syndromes to receive either fondaparinux (2.5 mg daily) or enoxaparin (1 mg per kilogram of body weight twice daily) for a mean of six days and evaluated death, myocardial infarction, or refractory ischemia at nine days (the primary outcome) ; major bleeding ; and their combination. Patients were followed for up to six months. The number of patients with primary-outcome events was similar in the two groups (579 with fondaparinux [5.8 percent] vs. 573 with enoxaparin [5.7 percent] ; hazard ratio in the fondaparinux group, 1.01 ; 95 percent confidence interval, 0.90 to 1.13), satisfying the noninferiority criteria. The number of events meeting this combined outcome showed a nonsignificant trend toward a lower value in the fondaparinux group at 30 days (805 vs. 864, P=0.13) and at the end of the study (1222 vs. 1308, P=0.06). The rate of major bleeding at nine days was markedly lower with fondaparinux than with enoxaparin (217 events [2.2 percent] vs. 412 events [4.1 percent] ; hazard ratio, 0.52 ; P
- Published
- 2006